The Abramson Cancer Center of the University of Pennsylvania
Last Modified: July 22, 2004
Conference Dates: Saturday, October 2, 2004
Conference Location: The Ace Center, Ridge Pike & Manor Road, Lafayette Hill, PA
Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania
Conference Objectives: At the completion of this conference, participants should be able to:
Who Should Attend: This education program is intended for medical oncologists, gastroenterologists and hepatologists, interventional radiologists, pathologists, hepatobiliary and transplant surgeons, surgical oncologists, oncology nurses and liver transplant coordinators, residents/fellows in training and other health care professionals involved in the treatment of patients with hepatocellular carcinoma and cirrhosis.
Conference Agenda: Hepatocellular cancer (HCC) remains a critical health problem worldwide, affecting half a million persons each year, making it the fifth most common malignancy in men, and the ninth most common in women. In the United States alone, HCC has doubled in the last 25 years, affecting all ethnic groups, both genders, and younger age groups. Due to the increasing prevalence of chronic liver disease from hepatitis C, the incidence and mortality of HCC will continue to rise significantly. Effective treatment is limited by the co-existence of cirrhosis in many of these patients.
This one-day course is directed at practicing and in-training physicians, surgeons and nurses in both the academic and community setting. Nationally and internationally recognized Penn faculty and guest speakers will present the latest information on the epidemiological trends, molecular mechanisms, viral etiologies, screening, and prevention of HCC. Recent advances in diagnostic imaging, as well as the limitations, will be discussed. A review of clinical and histopathologic features of HCC will identify factors associated with poor prognosis and clarify numerous staging systems.
The growing role of a multidisciplinary approach in the treatment of hepatocellular carcinoma and state-of-the-art advances will be reviewed, including percutaneous and laparoscopic ablative techniques, chemoembolization, surgical resection and transplantation, and adjuvant therapy following resection or liver replacement. Additionally, novel approaches to the treatment of advanced disease with systemic chemotherapy will be presented. Interactive case studies will reinforce the basic principles of diagnosis and illustrate various decision trees involved in the treatment strategies.
Continuing Education: Yes
Registration Information: The registration deadline is Friday, September 17, 2004. To register, fill out the below online registration form or send in the form.
Conference Fees: The registration fee is $125.00 for physicians and $75.00 for nurses and other health care professionals. Registration includes tuition, conference materials, lunch, and refreshment breaks as specified in the program agenda. Return form with a check made payable to: Trustees, University of Pennsylvania, 3400 Spruce Street, 16 Penn Tower, Philadelphia, PA 19104-4283, Attention: Mary Graham. Registrations may be faxed to (215) 614-1854. Checks must be received by Friday, September 17, 2004.
Jan 3, 2011 - Radiofrequency ablation appears to be safe and effective for the treatment of hepatocellular carcinoma among patients with cirrhosis, according to a study published online Oct. 21 in Hepatology.
Jan 3, 2011
Jul 6, 2011